Navigation Links
AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
Date:10/1/2013

NORTH CHICAGO, Ill., Oct. 1, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that new data from its phase II hepatitis C clinical development program will be presented at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., November 1-5, 2013. In total, eight abstracts will be presented, four of which include additional analyses from the phase IIb AVIATOR study. The data examine sustained virologic response (SVR) concordance, patient adherence to the regimen, patient reported outcomes and the impact of ribavirin dose reduction.  

The Liver Meeting will precede AbbVie's reporting of initial results from the pivotal phase III clinical trials of the safety and efficacy of AbbVie's investigational triple direct-acting antiviral (DAA) regimen for the treatment of hepatitis C. Reporting of those results is expected to begin later this year.

"At AbbVie, we are committed to researching new therapies that maximize sustained virologic response  with the hope of providing much needed new options for people with hepatitis C," said Barry Bernstein, M.D., vice president, infectious disease development, AbbVie. "We are very encouraged as we await top-line results from our phase III program, which we will share later this year."

Additionally, the oral presentation at AASLD will provide results from the PEARL-I study evaluating an interferon- and ribavirin-free, two-DAA investigational regimen in genotype 1b treatment-naïve patients and prior null responders. AbbVie is also investigating drug combinations for additional genotypes and next generations of DAAs as part of their ongoing commitment to the HCV community.

A brief summary of AbbVie's abstract titles is presented below.

About AbbVie's HC
'/>"/>

SOURCE AbbVie Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
2. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
3. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
4. AbbVie Declares Quarterly Dividend
5. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
6. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
7. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
8. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
9. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
10. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
11. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014  AxelaCare Health Solutions, ... services, announced today that it has acquired Advanced Care, ... intravenous therapy provider.  Terms of the transaction were not ... AxelaCare,s intravenous solutions pharmacies to 18 nationwide and expands ... New York - New Jersey ...
(Date:10/2/2014)... Intarcia Therapeutics, Inc. today announced successful top-line results ... for ITCA 650 (exenatide, delivered continuously once or twice ... trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical ... 650 in patients with type 2 diabetes against placebo. ... to placebo for both 40 mcg and 60 mcg ...
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014  Columbia ... that its subsidiary, Molecular Profiles Ltd., is set to ... annual CPhI/ICSE Worldwide event in Paris ... the rapid development of both standard and complex drug ... which incorporates the company,s existing formulation and analytical development ...
Breaking Medicine Technology:AxelaCare Health Solutions Acquires Advanced Care of New York 2AxelaCare Health Solutions Acquires Advanced Care of New York 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3
... Presented at the World Muscle Society International ... PTC Therapeutics, Inc.,(PTC), a biopharmaceutical company ... small-molecule drugs targeting,post-transcriptional control mechanisms, today announced ... of PTC124 in patients with Duchenne muscular,dystrophy ...
... Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) ... clinical and preclinical data on its lead ... the American Association for,Cancer Research (AACR), National ... and Treatment of Cancer (EORTC) entitled,"International Conference ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... your risk for high blood pressure, a new study suggests. ... within 109 yards of a busy road had a 22 ... living at least half a mile away, researchers report. ... our physical environment on our health and well-being," said lead ...
(Date:10/2/2014)... by scientists at The University of Nottingham could lead ... painkiller. , A drug resulting from the research, published ... offer new hope to sufferers of chronic pain conditions ... painkillers are currently available. , The work, led by ... Sciences, in collaboration with David Bates, Professor of Oncology ...
(Date:10/1/2014)... modelling of the human eye, the brain of a ... and new technology, says a QUT leading robotics researcher. ... Engineering Faculty says the new study uses new computer ... high-density buildings or tunnels. , "This is a very ... putting two halves of a thing together because we,re ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... Reno, Nev. (PRWEB) October 01, 2014 ... through measuring abnormal circadian cellular changes throughout the body, ... Health, Inc. to better address the company’s breadth of ... wearable early breast cancer screening technology. , “Our initial ... breast cancer system which detects abnormal circadian cellular changes ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Medical discovery first step on path to new painkillers 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4
... in our nation, Americans are very optimistic about the ... recent nationwide survey sponsored by Abbott, nearly two-thirds (64%) ... cancer. ,"As an organization researching new options ... efforts will live up to the optimism expressed by ...
... Suffering from acute or chronic lower back pain? There ... Medicine Center locally in Fairview, N.J, which will ... are only a handful of these machines in Bergen ... center, who administers non-invasive Intervertebral Disc Decompression (IDD) therapy. ...
... A teenage girl has died of bird flu in Indonesia, taking ... to 79, a health ministry official said Friday. ... to hospital on the main island of Java, the official said. ... chicken at her home in Kendal district in Central Java, said ...
... politician Abdel Aziz al-Hakim returned to Iraq's holy city of ... ,Hakim, the head of one of the most ... in a trip that included medical tests in the United ... his headquarters in Najaf and will be there for a ...
... earlier believed, a new study carried out by the ... ,According to the satellite-based research undertaken by Frank ... precipitation has also kept pace. ,The findings ... to accurately predict precipitation on regional scales. ...
... Scientists at the Chinese University in Hong Kong have identified ... may hold clues to male infertility . ,As part ... defective versions of the protein. They found that the sperms ... those of normal mice. ,'(The protein) is involved ...
Cached Medicine News:Health News:Americans Optimistic About the War on Cancer 2Health News:Indonesian Teenager Dies of Bird Flu 2Health News:Top Iraqi Shiite Leader Returns Home 2Health News:World may Get Much Wetter With Global Warming Than Believed 2
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
MiniVes has been specifically designed for the doctors office and near patient testing and it uses normally freshly collected blood that shall be mixed manually by 15 complete inversion of the tube a...
Medicine Products: